A Triple-Regulated Oncolytic Adenovirus Carrying MicroRNA-143 Exhibits Potent Antitumor Efficacy in Colorectal Cancer.
KRAS
colorectal cancer
microRNA-143
oncolytic adenovirus
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
27 Mar 2020
27 Mar 2020
Historique:
received:
24
09
2019
accepted:
13
01
2020
entrez:
4
3
2020
pubmed:
4
3
2020
medline:
4
3
2020
Statut:
epublish
Résumé
The cancer-targeting gene virotherapy might be a useful strategy for the treatment of cancer, because it could combine the advantages of both gene therapy and virotherapy. This study aimed to construct a triple-regulated oncolytic adenovirus, Ad-RGD-Survivin-ZD55-miR-143, carrying the therapeutic gene miR-143 and evaluate its possible antitumor effect in colorectal cancer. We observed that miR-143 was lowly expressed in patients with colorectal cancer. The upregulation of miR-143 could inhibit cell proliferation and induce cell apoptosis by targeting KRAS in colorectal cancer cells. Then, Ad-RGD-Survivin-ZD55-miR-143 was successfully constructed in this study. Cells infected with Ad-RGD-Survivin-ZD55-miR-143 could inhibit cell proliferation, suppress cell migration and invasion, arrest cells at the G1 phase, and induce cellular apoptosis. At the same time, Ad-RGD-Survivin-ZD55-miR-143 decreased the expression of PARP-1 and KRAS protein
Identifiants
pubmed: 32123722
doi: 10.1016/j.omto.2020.01.005
pii: S2372-7705(20)30013-9
pmc: PMC7036723
doi:
Types de publication
Journal Article
Langues
eng
Pagination
219-229Informations de copyright
© 2020 The Authors.
Références
Lancet Oncol. 2016 Dec;17(12):1709-1719
pubmed: 27743922
Cancer Res. 2017 Apr 15;77(8):2052-2063
pubmed: 28143835
Br J Cancer. 2013 Apr 30;108(8):1757-64
pubmed: 23511557
Cells. 2019 May 26;8(5):
pubmed: 31130710
Cell Res. 2010 Mar;20(3):367-78
pubmed: 19918267
Cancer Sci. 2019 Feb;110(2):805-816
pubmed: 30536996
Cell Res. 2006 Nov;16(11):879-86
pubmed: 17102812
Neurotherapeutics. 2017 Apr;14(2):333-344
pubmed: 28265902
Lancet Oncol. 2013 Dec;14(13):1295-306
pubmed: 24239208
J Biol Chem. 2010 Jul 16;285(29):22003-16
pubmed: 20457603
Oncotarget. 2017 Sep 23;8(50):87837-87847
pubmed: 29152124
J Natl Compr Canc Netw. 2015 Jun;13(6):719-28; quiz 728
pubmed: 26085388
Carcinogenesis. 2015 May;36(5):528-37
pubmed: 25804644
J Clin Invest. 2017 Mar 1;127(3):761-771
pubmed: 28248199
Oncogene. 2009 Mar 12;28(10):1385-92
pubmed: 19137007
Science. 2008 Mar 28;319(5871):1789-90
pubmed: 18369137
J Surg Oncol. 2017 Jul;116(1):94-103
pubmed: 28407327
Ann Surg Oncol. 2018 Feb;25(2):431-438
pubmed: 29181680
Nat Protoc. 2007;2(5):1236-47
pubmed: 17546019
Nat Rev Cancer. 2014 Aug;14(8):559-67
pubmed: 24990523
Cancers (Basel). 2018 Sep 26;10(10):
pubmed: 30261620
Clin Colorectal Cancer. 2016 Dec;15(4):e175-e182
pubmed: 27247088
Am J Physiol Gastrointest Liver Physiol. 2015 Feb 1;308(3):G179-87
pubmed: 25477374
Cell Death Dis. 2017 Oct 12;8(10):e3101
pubmed: 29022908
Am J Transl Res. 2016 Sep 15;8(9):3822-3830
pubmed: 27725862
Adv Drug Deliv Rev. 2001 Nov 19;52(3):165-76
pubmed: 11718941
Pol J Pathol. 2012 Jun;63(2):87-92
pubmed: 22864776
Cancer. 2012 Nov 1;118(21):5217-26
pubmed: 22517373
Hum Gene Ther. 2014 Jan;25(1):3-11
pubmed: 24444179
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Theranostics. 2015 Jul 13;5(10):1122-43
pubmed: 26199650
Dis Colon Rectum. 2002 Apr;45(4):491-501
pubmed: 12006931
Int J Urol. 2017 May;24(5):342-351
pubmed: 28326624